RxDoctor Payments Data

Brian Gotkin, MD

Pulmonary Disease · Hollywood, FLNPI 1891782926

Payments from drug & device makers

$27,916in general payments, 2019–2025

Across 156 payments — averaging $178.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$17K
  • GSK$6K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Genentech USA, Inc.$273
  • Harmony Biosciences LLC$228
  • Boehringer Ingelheim$216
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$2,91042%
  • Speaking & faculty fees$1,00014%
  • Food & beverage$2,86041%
  • Education$1552%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,916 in reported general payments places this provider in the 75th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$161,815
Medicare patients
645
Services billed
1,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate57$720,951
Trelegy ElliptaFluticasone/Umeclidin/Vilanter403$301,845
OpsumitMacitentan24$293,282
AdempasRiociguat13$180,200
Prolastin CAlpha-1-Proteinase Inhibitor13$119,107
Breztri AerosphereBudesonide/Glycopyr/Formoterol163$118,408
Breo ElliptaFluticasone/Vilanterol205$103,532
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr130$69,203
SymbicortBudesonide/Formoterol Fumarate160$45,843
XolairOmalizumab17$34,347
Stiolto RespimatTiotropium Br/Olodaterol Hcl44$32,051
EliquisApixaban41$31,471
Spiriva RespimatTiotropium Bromide27$24,909
Spiriva HandihalerTiotropium Bromide28$18,198
Albuterol Sulfate HfaAlbuterol Sulfate291$10,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$216$777,912128 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$6,401$474,581738 claims
Actelion Pharmaceuticals US, Inc.Opsumit$110$293,28224 claims
BayerAdempas$60$180,20013 claims
AstraZenecaBreztri Aerosphere, Symbicort$16,558$164,252323 claims
Grifols USA, LLCProlastin C$174$119,10713 claims
PfizerEliquis$16$31,47141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →